We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Multitarget Fecal Immunochemical Test Validated for Colorectal Cancer

By LabMedica International staff writers
Posted on 08 Aug 2021
Print article
A novel protein-based multitarget fecal immunochemical test (mFIT) for colorectal cancer (CRC) screening was superior to conventional FIT in detecting advanced neoplasia, particularly advanced adenomas (Photo courtesy of Mike Bassett)
A novel protein-based multitarget fecal immunochemical test (mFIT) for colorectal cancer (CRC) screening was superior to conventional FIT in detecting advanced neoplasia, particularly advanced adenomas (Photo courtesy of Mike Bassett)
Colorectal cancer (CRC) starts in the colon or the rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped together because they have many features in common.

Scientists study screening tests to find those with the fewest harms and most benefits. Cancer screening trials also are meant to show whether early detection (finding cancer before it causes symptoms) helps a person live longer or decreases a person's chance of dying from the disease. The fecal immunochemical test (FIT) is used in colorectal cancer (CRC) screening, yet it leaves room for improvement.

Medical Scientists at the Netherlands Cancer Institute (Amsterdam, The Netherlands) collected samples for FIT from 1,284 patients from a Dutch screening population. They were classified according to their most advanced lesion: 47 with CRC, 135 with advanced adenomas, 30 with advanced serrated polyps, 250 with non-advanced adenomas, and 53 with non-advanced serrated polyps, along with 769 controls. The team developed assays for nine protein biomarkers and determined that the combination of hemoglobin, calprotectin, and serpin family F member 2, defined as the mtFIT, had the best diagnostic performance, based on classification and regression tree analysis.

The investigators applied classification and regression tree (CART) analysis biomarker concentrations to identify the optimal combination for detecting advanced neoplasia. They reported that with identical specificities of 96.6%, mtFIT had a similar sensitivity for CRC compared with FIT (78.7% versus 80.9%, respectively), and significantly greater sensitivity for advanced neoplasia (42.9% versus 37.3%). This increase in cross-validated sensitivity was completely due to an increased sensitivity for advanced adenomas (37.8% for mtFIT versus 28.1% for FIT. The cross-validated sensitivities of mtFIT and FIT for advanced serrated polyps were equal at 10.0%.

Meike de Wit, PhD, a molecular biologist and co-author of the study, said, “This study provides clinical validation of a mFIT with higher accuracy for detecting advanced neoplasia, in particular advanced adenomas, compared with FIT. This enables early detection and interception at a premalignant stage rather than an early invasive stage, which could have a major effect on quality of life. Moreover, compared with FIT screening, mFIT-based screening could lead to a further reduction in CRC incidence and death.”

The authors concluded that compared with FIT, the mtFIT showed better diagnostic accuracy in detecting advanced neoplasia because of an increased detection of advanced adenomas. Moreover, early health technology assessment indicated that these results provide a sound basis to pursue further development of mtFIT as a future test for population-based CRC screening. The study was published on July 20, 2021 in the journal Annals of Internal Medicine.

Related Links:

Netherlands Cancer Institute

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.